{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:46:24Z","timestamp":1794491184438,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) is an innovative treatment against peritoneal carcinomatosis. Doxorubicin is a common intra-venous chemotherapy used for peritoneal carcinomatosis and for PIPAC. This study evaluated the impact of increased PIPAC intraperitoneal pressure on the distribution and cell penetration of doxorubicin in a sheep model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Doxorubicin was aerosolized using PIPAC into the peritoneal cavity of 6 ewes (pre-alpes breed):\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20093 with 12\u2009mmHg intraperitoneal pressure (\u201cgroup 12\u201d) and N\u2009=\u20093 with 20\u2009mmHg (\u201cgroup 20\u201d). Samples from peritoneum (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20096), ovarian (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091), omentum (N\u2009=\u20091) and caecum (N\u2009=\u20091) were collected for each ewe. The number of doxorubicin positive cells was determined using the ratio between doxorubicine fluorescence-positive cell nuclei (DOXO+) over total number of DAPI positive cell nuclei (DAPI+). Penetration depth (\u03bcm) was defined as the distance between the luminal surface and the location of the deepest DOXO+ nuclei over the total number of cell nuclei that were stained with DAPI. Penetration depth (\u03bcm) was defined as the distance between the luminal surface and the location of the deepest DOXO+ nuclei.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DOXO+ nuclei were identified in 87% of samples. All omental samples, directly localized in front of the nebulizer head, had 100% DOXO+ nuclei whereas very few nuclei were DOXO+ for caecum. Distribution patterns were not different between the two groups but penetration depth in ovary and caecum samples was significantly deeper in group 20.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study showed that applying a higher intra-peritoneal pressure during PIPAC treatment leads to a deeper penetration of doxorubicin in ovarian and caecum but does not affect distribution patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-07955-w","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T04:03:33Z","timestamp":1619409813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pressurized intra-peritoneal aerosol chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model"],"prefix":"10.1186","volume":"21","author":[{"given":"Myriam","family":"Mimouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Adenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Letheule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tarrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Dahirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lilin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Lecuelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"G\u00e9lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Fauconnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Vialard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Huchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Chavatte-Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"7955_CR1","unstructured":"European Society of Gynaecological Oncology ESGO Ovarian Cancer Surgery Guidelines_v2, http:\/\/Guidelines.Esgo.Org\/Media\/2017\/03\/ESGO_ovarian_cancer_surgery_brA5_V01-Website.Pdf."},{"key":"7955_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"95","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Thomacruz R, Armstrong D, et al. Recurrent Micropapillary Serous Ovarian Carcinoma. Cancer. 2002;95:791\u2013800. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1248.","journal-title":"Cancer"},{"key":"7955_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the Ovary. New England J Med. 2004;351:2519\u201329. https:\/\/doi.org\/10.1056\/NEJMra041842.","journal-title":"New England J Med"},{"key":"7955_CR4","doi-asserted-by":"publisher","unstructured":"Al Rawahi T, Lopes A, Bristow E, et al. \u2018Surgical Cytoreduction for Recurrent Epithelial Ovarian Cancer. Cochrane Database Systematic Rev. 2013;2. https:\/\/doi.org\/10.1002\/14651858.CD008765.pub3.","DOI":"10.1002\/14651858.CD008765.pub3"},{"key":"7955_CR5","doi-asserted-by":"publisher","unstructured":"Hanker LC, Loibl S, Burchati N, et al. The Impact of Second to Sixth Line Therapy on Survival of Relapsed Ovarian Cancer after Primary Taxane\/Platinum-Based Therapy. Ann Oncol. 2012;23. https:\/\/doi.org\/10.1093\/annonc\/mds203.","DOI":"10.1093\/annonc\/mds203"},{"key":"7955_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol. 2014;32:13. https:\/\/doi.org\/10.1200\/JCO.2013.51.4489.","journal-title":"J Clin Oncol"},{"key":"7955_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3802\/jgo.2015.26.2.87","volume":"26","author":"J. Prat and FIGO Committee on Gynecologic Oncology","year":"2015","unstructured":"J. Prat and FIGO Committee on Gynecologic Oncology. FIGO\u2019s Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication. J Gynecol Oncol. 2015;26:2. https:\/\/doi.org\/10.3802\/jgo.2015.26.2.87.","journal-title":"J Gynecol Oncol"},{"key":"7955_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","volume":"26","author":"W Sola\u00df","year":"2012","unstructured":"Sola\u00df W, Alexander H, Nadiradze G, et al. Description of a Novel Approach for Intraperitoneal Drug Delivery and the Related Device. Surgical Endoscopy. 2012;26:1849\u201355. https:\/\/doi.org\/10.1007\/s00464-012-2148-0.","journal-title":"Surgical Endoscopy"},{"key":"7955_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00464-011-1964-y","volume":"26","author":"W Sola\u00df","year":"2012","unstructured":"Sola\u00df W, Herbette A, Schwartz T, et al. Therapeutic Approach of Human Peritoneal Carcinomatosis with Dbait in Combination with Capnoperitoneum: Proof of Concept. Surgical Endoscopy. 2012;26:3. https:\/\/doi.org\/10.1007\/s00464-011-1964-y.","journal-title":"Surgical Endoscopy"},{"key":"7955_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1245\/s10434-012-2840-2","volume":"20","author":"A Blanco","year":"2013","unstructured":"Blanco A, Giger-Parbst U, Sola\u00df W, et al. Renal and Hepatic Toxicities after Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Ann Surgical Oncol. 2013;20:7. https:\/\/doi.org\/10.1245\/s10434-012-2840-2.","journal-title":"Ann Surgical Oncol"},{"key":"7955_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ygyno.2013.11.022","volume":"132","author":"CB Tempfer","year":"2014","unstructured":"Tempfer CB, Celik I, Sola\u00df W, et al. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Cisplatin and Doxorubicin in Women with Recurrent, Platinum-Resistant Ovarian Cancer: Preliminary Clinical Experience. Gynecol Oncol. 2014;132:2. https:\/\/doi.org\/10.1016\/j.ygyno.2013.11.022.","journal-title":"Gynecol Oncol"},{"key":"7955_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-0035-1560004","volume":"35","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB, Rezniczek GA, et al. Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study. Anticancer Res. 2015;35:12. https:\/\/doi.org\/10.1055\/s-0035-1560004.","journal-title":"Anticancer Res"},{"key":"7955_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ygyno.2015.02.009","volume":"137","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB, Winnekendonk G, Sola\u00df W, et al. Pressurized Intraperitoneal Aerosol Chemotherapy in Women with Recurrent Ovarian Cancer: A Phase 2 Study. Gynecologic Oncol. 2015;137:2. https:\/\/doi.org\/10.1016\/j.ygyno.2015.02.009.","journal-title":"Gynecologic Oncol"},{"key":"7955_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejso.2017.03.019","volume":"43","author":"M H\u00fcbner","year":"2017","unstructured":"H\u00fcbner M, Grass F, Texeira-Farinha H, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy - Practical Aspects. Eur J Surgical Oncol. 2017;43:6. https:\/\/doi.org\/10.1016\/j.ejso.2017.03.019.","journal-title":"Eur J Surgical Oncol"},{"key":"7955_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejso.2015.06.001","volume":"41","author":"K Odendahl","year":"2015","unstructured":"Odendahl K, Sola\u00df W, Demtr\u00f6der C, et al. Quality of Life of Patients with End-Stage Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surgical Oncol. 2015;41:10. https:\/\/doi.org\/10.1016\/j.ejso.2015.06.001.","journal-title":"Eur J Surgical Oncol"},{"key":"7955_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00404-018-4784-7","volume":"298","author":"C Tempfer","year":"2018","unstructured":"Tempfer C, Giger-Pabst U, Hilal Z, et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Carcinomatosis: Systematic Review of Clinical and Experimental Evidence with Special Emphasis on Ovarian Cancer. Arch Gynecol Obstetrics. 2018;298:2. https:\/\/doi.org\/10.1007\/s00404-018-4784-7.","journal-title":"Arch Gynecol Obstetrics"},{"key":"7955_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1515\/pp-2018-0114","volume":"3","author":"N Bakrin","year":"2018","unstructured":"Bakrin N, Tempfer C, Scambia G, et al. PIPAC-OV3: A Multicenter, Open-Label, Randomized, Two-Arm Phase III Trial of the Effect on Progression-Free Survival of Cisplatin and Doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. Chemotherapy Alone in Patients with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Pleura and Peritoneum. 2018;3:3. https:\/\/doi.org\/10.1515\/pp-2018-0114.","journal-title":"Pleura and Peritoneum"},{"key":"7955_CR18","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, et al. Pressurised Intraperitoneal Aerosol Chemotherapy: Rationale, Evidence, and Potential Indications. Lancet Oncol. 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(19)30318-3.","journal-title":"Lancet Oncol"},{"key":"7955_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejso.2018.02.014","volume":"44","author":"M Nowacki","year":"2018","unstructured":"Nowacki M, Alyami M, Villeneuve L, et al. Multicenter Comprehensive Methodological and Technical Analysis of 832 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Interventions Performed in 349 Patients for Peritoneal Carcinomatosis Treatment: An International Survey Study\u2019. Eur J Surgical Oncol. 2018;44:7. https:\/\/doi.org\/10.1016\/j.ejso.2018.02.014.","journal-title":"Eur J Surgical Oncol"},{"key":"7955_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"73","author":"KK Karukstis","year":"1998","unstructured":"Karukstis KK, Thompson EH, Whiles JA, et al. Deciphering the Fluorescence Signature of Daunomycin and Doxorubicin. Biophysical Chem. 1998;73:3. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1248.","journal-title":"Biophysical Chem"},{"key":"7955_CR21","first-page":"4","volume":"44","author":"SL Zeger","year":"1988","unstructured":"Zeger SL, Liang KY, Albert PS. Models for Longitudinal Data: A Generalized Estimating Equation Approach. Biometrics. 1988;44:4 https:\/\/pubmed.ncbi.nlm.nih.gov\/3233245\/.","journal-title":"Biometrics"},{"key":"7955_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical Research Methodologies in Diagnosis and Staging of Patients with Peritoneal Carcinomatosis. Cancer Treatment Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treatment Res"},{"key":"7955_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12957-017-1109-4","volume":"15","author":"V Khosrawipour","year":"2017","unstructured":"Khosrawipour V, Diaz-Carballo D, Acikelli AH, et al. Cytotoxic Effect of Different Treatment Parameters in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) on the in Vitro Proliferation of Human Colonic Cancer Cells. World J Surgical Oncol. 2017;15:43. https:\/\/doi.org\/10.1186\/s12957-017-1109-4.","journal-title":"World J Surgical Oncol"},{"key":"7955_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJP, et al. Distribution Pattern and Penetration Depth of Doxorubicin after Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a Postmortem Swine Model. J Cancer Res Clin Oncol. 2016;142:11. https:\/\/doi.org\/10.1007\/s00432-016-2234-0.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7955_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/ol.2019.10162","volume":"17","author":"T Khosrawipour","year":"2019","unstructured":"Khosrawipour T, Schubert J, Khosrawipour V. Particle Stability and Structure on the Peritoneal Surface in Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) Analysed by Electron Microscopy: First Evidence of a New Physical Concept for PIPAC. Oncology Lett. 2019;17:6. https:\/\/doi.org\/10.3892\/ol.2019.10162.","journal-title":"Oncology Lett"},{"key":"7955_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00464-017-5652-4","volume":"32","author":"A Bellendorf","year":"2018","unstructured":"Bellendorf A, Khosrawipour V, Khosrawipour T, et al. Scintigraphic Peritoneography Reveals a Non-Uniform 99mTc-Pertechnetat Aerosol Distribution Pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a Swine Model. Surgical Endoscopy. 2018;32:1. https:\/\/doi.org\/10.1007\/s00464-017-5652-4.","journal-title":"Surgical Endoscopy"},{"key":"7955_CR27","doi-asserted-by":"publisher","unstructured":"Kakchekeeva T, Demtr\u00f6der C, Herath NI, et al. In Vivo Feasibility of Electrostatic Precipitation as an Adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (EPIPAC). Ann Surgical Oncol. 2016. https:\/\/doi.org\/10.1245\/s10434-016-5108-4.","DOI":"10.1245\/s10434-016-5108-4"},{"key":"7955_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1515\/pp-2016-0005","volume":"1","author":"M Reymond","year":"2016","unstructured":"Reymond M, Demtr\u00f6der C, Sola\u00df W, et al. Electrostatic Precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (EPIPAC): First in-Human Application. Pleura and Peritoneum. 2016;1:2. https:\/\/doi.org\/10.1515\/pp-2016-0005.","journal-title":"Pleura and Peritoneum"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07955-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-07955-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07955-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T04:08:42Z","timestamp":1619410122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07955-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7955"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07955-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-31578\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-31578\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was approved by the local ethics committee of animal experimentation of the National Veterinary School of Alfort and was registered under \u201cAPAFIS 2016113016134972\u201d number by the relevant national authorities. All anaesthesia, analgesia and surgical procedures were carried out by an habilitated and expert team.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"461"}}